Povorcitinib for Hidradenitis Suppurativa
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the safety and effectiveness of a new treatment called povorcitinib for teenagers with moderate to severe hidradenitis suppurativa, a skin condition that causes painful lumps under the skin. Over 54 weeks, participants will receive one of two different doses to evaluate its effects on their bodies and its impact on their skin condition. Suitable candidates for this trial are teenagers who have had the condition for at least 3 months and have not responded well to other treatments like antibiotics or biologics. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that povorcitinib is generally safe for people. Studies have found that using povorcitinib to treat hidradenitis suppurativa, a skin condition, does not increase side effects, even at different doses. Earlier studies reported consistent safety for povorcitinib, with no major safety problems. Overall, the treatment appears safe based on current information.12345
Why are researchers excited about this trial's treatments?
Researchers are excited about Povorcitinib for Hidradenitis Suppurativa because it works differently from current treatments. Most available options, like antibiotics and anti-inflammatory drugs, aim to reduce infection and inflammation but don't always tackle the root cause of the disease. Povorcitinib is unique because it targets specific pathways involved in the inflammatory process, potentially offering more effective relief. This targeted approach could mean fewer side effects and a more significant impact on the condition's progression, which is why researchers are hopeful about its potential.
What evidence suggests that this trial's treatments could be effective for hidradenitis suppurativa?
Research has shown that povorcitinib offers promising results for treating hidradenitis suppurativa (HS), a skin condition that causes painful lumps. In one study, nearly 60% of patients experienced significant improvement by week 24. This trial will test povorcitinib at different doses, with participants receiving either Dose A or Dose B for 54 weeks. Previous studies have demonstrated that both doses were more effective than a placebo (a harmless pill used for comparison). By week 16, patients noticed a clear reduction in abscesses and swollen bumps on their skin. Overall, these findings suggest povorcitinib could be effective for people with moderate to severe HS.12678
Who Is on the Research Team?
Incyte Medical Monitor
Principal Investigator
Incyte Corporation
Are You a Good Fit for This Trial?
Adolescents aged 12-17 with moderate to severe hidradenitis suppurativa (HS), weighing at least 30 kg, who haven't responded well to traditional treatments. Participants must have had HS for a minimum of three months and have at least five abscesses or nodules. They should be able to follow the study rules and agree to use contraception.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive povorcitinib for 54 weeks to evaluate pharmacokinetics, safety, and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Povorcitinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Incyte Corporation
Lead Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School